

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

GENZYME CORPORATION,
Petitioner

v.

GENENTECH, INC. AND CITY OF HOPE,
Patent Owners

U.S. Patent No. 6,331,415
Appl. No. 07/205,419, filed June 10, 1988
Issued: Dec. 18, 2001

Title: Methods of Producing Immunoglobulins, Vectors
and Transformed Host Cells for Use Therein

IPR Trial No. IPR2016-00383

**DECLARATION OF MARGARET H. BARON, M.D., PH.D.,
IN SUPPORT OF GENZYME'S PETITION FOR
INTER PARTES REVIEW OF U.S. PATENT NO. 6,331,415**

TABLE OF CONTENTS

	<u>Page</u>
I. BACKGROUND AND QUALIFICATIONS, PREVIOUS TESTIMONY, AND COMPENSATION	1
A. Background and Qualifications	1
B. Prior Testimony	5
C. Compensation	5
II. MATERIALS AND INFORMATION CONSIDERED AND RELIED UPON.....	5
III. LEGAL FRAMEWORK FOR MY ANALYSIS	6
A. Anticipation	6
B. Obviousness.....	7
C. Person of Ordinary Skill in the Art	9
D. Claim Construction.....	10
IV. SUMMARY OF OPINIONS.....	11
V. OVERVIEW OF THE '415 PATENT TECHNOLOGY AND THE CHALLENGED CLAIMS	11
A. Background of the Technology: Antibody Structure, Function and Production.....	11
B. The Subject Matter of the Challenged Claims	16
VI. THE STATE OF PRIOR ART RDNA ANTIBODY EXPRESSION IN APRIL 1983 AND OWNERS' ARGUMENTS DURING REEXAM	24
B. Prior Art Platform Technologies for Expressing Foreign Genes in Mammalian Cells	25
1. The Axel Patent.....	25

TABLE OF CONTENTS

(continued)

	<u>Page</u>
2. The Southern Reference.....	28
C. The Prior Art Taught Expression of Single Immunoglobulin Chains in Transformed Mammalian Host Cells.....	29
D. Owners' Arguments During Reexamination Regarding the Axel Patent.....	30
VII. STATEMENT OF GROUNDS FOR THE UNPATENTABILITY OF THE CHALLENGED CLAIMS	33
A. The Salser Patent Anticipates Claims 1-4, 9, 11, 12, 15-20 and 33 Under 35 U.S.C. § 102(e).....	33
1. Overview of the Salser Patent Disclosures.....	33
2. The Salser Patent Anticipates Independent Claims 1, 15, 17, 18 and 33.....	38
a. Independent Process Claim 1	38
b. Independent Process Claim 33	49
c. Independent Composition Claims 15 and 17	49
d. Independent Composition Claim 18.....	50
3. The Salser Patent Anticipates Dependent Claims 2, 3, 4, 9, 11, 12, 16, 19 and 20.....	50
B. All of the Challenged Claims Are Obvious Over Salser in View of Ochi (I).....	53
1. Claims 1-4, 9, 11, 12, 15-20 and 33.....	53
2. Claim 14.....	54
C. Claims 2, 18, and 20 Are Also Obvious Based on Salser in Combination with Southern	55

1. I, Margaret H. Baron, MD, PhD, have been retained by Mayer Brown LLP, counsel for Genzyme. I understand that Genzyme has petitioned for *inter partes* review of U.S. Patent No. 6,331,415 ("the '415 patent," Ex. 1001) and requested that the United States Patent and Trademark Office cancel Claims 1-4, 9, 11, 12, 14-20 and 33 of the '415 patent ("the challenged claims") as unpatentable. The following discussion and analyses address and are presented in support of the bases for Genzyme's petition.

I. BACKGROUND AND QUALIFICATIONS, PREVIOUS TESTIMONY, AND COMPENSATION

A. Background and Qualifications

2. As further detailed in my CV, attached as Exhibit A, I received a bachelor's degree from Harvard University (Cambridge, MA) in 1976 *summa cum laude* in Biochemical Sciences. My senior thesis involved a structural analysis of the aqueous central cavity (containing the active site) of the enzyme Aspartate Transcarbamylase (ATCase) of *Escherichia coli*. The research for this thesis was performed in the Department of Chemistry under the direction of the late William N. Lipscomb, PhD (Nobel Laureate, 1976).

3. In September 1976, I started medical and PhD graduate studies in the Harvard-M.I.T. Program in Health Sciences and Technology (HST Program) at Harvard Medical School (Boston, MA) and Massachusetts Institute of Technology

(M.I.T., Cambridge MA). I took medical school courses at Harvard Medical School and at M.I.T. and graduate courses in Biology at M.I.T. From July 1978 through December 1981, I performed PhD dissertation research in the laboratory of Nobel Laureate (1975) David Baltimore, PhD, in the Department of Biology at M.I.T. This research focused on the mechanism of replication of poliovirus, using protein and RNA nucleic acid biochemistry techniques. I received my PhD from M.I.T. in March, 1982.

4. From January 1982 through December 1982, I returned to Harvard Medical School to complete the clinical clerkship requirements for my MD degree, which was awarded in June 1983.

5. From January 1983 through June 1983, I returned to David Baltimore's laboratory at M.I.T. and carried out recombinant DNA studies of Abelson murine leukemia virus.

6. From July 1983 through June 1984, I completed an internship in Internal Medicine at Massachusetts General Hospital. I subsequently became licensed in medicine and surgery (Diplomate, National Board of Medical Examiners) in the Commonwealth of Massachusetts.

7. From August 1984 through March 1989, I was a postdoctoral fellow in the laboratory of Tom Maniatis, PhD, in the Department of Biochemistry and Molecular Biology at Harvard University (Cambridge, MA), where I analyzed the

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.